Patients can be relapsers to rituxan based therapy and not totally refractory. some of these could have some tumor shrinkage when re-challanged to rituxan. how many i am not sure perhaps someone on here knows better than I. A durable response in this population probably means the TRIL drug is doing something since they did - after all - relapse to first line rituxan
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.